StimAire, a US-based injectable neuromodulation company developing medical devices for obstructive sleep apnoea (OSA), announced on Monday that it has named Arthur Rascon as its new chief operating officer (COO), effective 22 July 2024.
Rascon has more than two decades of experience in operational leadership and a proven track record of driving innovation and commercialisation in the medical device industry. He has worked as the chief executive officer at Valencia Technologies Corporation. He has worked as senior director of Manufacturing Engineering at Medtronic Diabetes, vice president of Manufacturing and Quality Engineering, and senior director of Product Engineering at Advanced Bionics.
Tarek Makansi PhD, StimAire president and chief technology officer, said, 'We are thrilled to welcome Arthur Rascon to the full-time leadership team. Arthur will move our company and product forward from a demonstrated technology to a certified medical device offering with the goal of improving the lives of those affected by obstructive sleep apnoea.'
Medivir secures European patent for fostrox and lenvatinib combination in liver cancer treatment
Workflow Services completes one-year pilot and expands Colorectal Cancer Screening Education Program
RedHill Biopharma to submit Talicia for UK marketing authorisation
bioMérieux receives FDA clearance for VITEK COMPACT PRO to combat antimicrobial resistance
BiBBInstruments successfully demonstrates EndoDrill GI in live biopsy procedure
Evommune enrols first patient in EVO301 Phase 2 trial
Telix Pharmaceuticals' Illuccix approved in Brazil
Physiomics secures GBP102,000 contract with UK biotech for ADC therapy development
Revelation Biosciences reports Gemini's anti-inflammatory potential in PBMC study
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer